Application of Ramucirumab Exposure-Response Modeling to Support Dose Selection for Post Marketing Studies in Patients with Gastric Cancer

被引：0
|
作者：
O'Brien, Lisa [1 ]
Gao, Ling [2 ]
Heathman, Michael [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Bridgewater, NJ USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-36
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [1] A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis
    Hu, Chuanpu
    Yao, Zhenling
    Chen, Yang
    Randazzo, Bruce
    Zhang, Liping
    Xu, Zhenhua
    Sharma, Amarnath
    Zhou, Honghui
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 (04) : 523 - 535
  • [2] Use of a Biomarker in Exposure-Response Analysis to Support Dose Selection for Fingolimod
    Lee, J-Y
    Wang, Y.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (08):
  • [3] Exposure-Response Modeling in Support of Phase 3 Dose Selection of MK-3222 for Treatment of Psoriasis
    Zandvliet, Anthe
    Li, Hanbin
    Wada, Russ
    Nograles, Kristine
    Shames, Rich
    Mehrotra, Devan
    Allerheiligen, Sandy
    Kerbusch, Thomas
    Mogg, Robin
    Hanley, Bill
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S41 - S42
  • [4] A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan
    Yucherng Chen
    Taeko Katayose
    Soshi Nagaoka
    Yongzhe Piao
    Kensei Yamaguchi
    Hiroya Asou
    Gastric Cancer, 2021, 24 : 1320 - 1329
  • [5] A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan
    Chen, Yucherng
    Katayose, Taeko
    Nagaoka, Soshi
    Piao, Yongzhe
    Yamaguchi, Kensei
    Asou, Hiroya
    GASTRIC CANCER, 2021, 24 (06) : 1320 - 1329
  • [6] Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
    Thakre, Neha
    Goebel, Aline
    Winzenborg, Insa
    Suleiman, Ahmed A.
    D'Cunha, Ronilda
    Mensing, Sven
    Liu, Wei
    Pang, Yinuo
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (03) : 847 - 857
  • [7] EXPOSURE-RESPONSE RELATIONSHIP OF FILIBUVIR IN HCV INFECTED PATIENTS: APPLICATION TO DOSE SELECTION FOR COMBINATION THERAPY
    Neelakantan, S.
    Purohit, V. S.
    O'Gorman, M.
    Hammond, J.
    Tensfeldt, T. G.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S119 - S120
  • [8] Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients
    Wang, Huanhuan
    Hu, Xiaoyun
    Wang, Teng
    Cui, Cheng
    Jiang, Ji
    Dong, Kai
    Chen, Shuai
    Jin, Chunyan
    Zhao, Qian
    Du, Bin
    Hu, Pei
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [9] Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
    Bhatnagar, Sumit
    Schlachter, Louisa
    Eckert, Doerthe
    Stodtmann, Sven
    Liu, Wei
    Lacerda, Ana P.
    Mohamed, Mohamed-Eslam F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (05) : 1240 - 1251
  • [10] Rilotumumab Exposure-Response Relationship in Patients with Advanced or Metastatic Gastric Cancer
    Doshi, Sameer
    Gisleskog, Per Olsson
    Zhang, Yilong
    Zhu, Min
    Oliner, Kelly S.
    Loh, Elwyn
    Ruixo, Juan Jose Perez
    CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2453 - 2461
12345